Enfermedad
Colorectal cancer
CIE-10: C18–C20 — Malignant neoplasm of colon, rectosigmoid junction and rectum
Cifras clave
Solo valores publicados. Cada recuadro abre la sección que incluye su fuente, su año y su criterio.
- Intervalos de costos del tratamiento 5 intervalos publicados, cada uno con su fuente en la página de la fila
- Supervivencia a cinco años 55.7% 95% CI 55.4–55.9 · 2019–2021
- Hospitales con un registro publicado 8 para esta enfermedad, cada uno con su fuente publicada
- Ensayos clínicos 123 en reclutamiento o aún sin reclutar, según lo publicado
Detalles de la enfermedad
- Nombre en inglés
- Malignant neoplasm of colon, rectosigmoid junction and rectum
También conocido como
- CRC
- Colon cancer
- Rectal cancer
Intervalos de costos del tratamiento
Todos los intervalos de abajo se publican sobre una misma base de facturación: Antes del reembolso. Las fuentes no publican ninguna cifra posterior al reembolso, así que aquí no se muestra ninguna.
| Ruta de tratamiento | Intervalo de costos | Base del precio | Año de los datos |
|---|---|---|---|
| Cirugía | 48000 – 67000 CNY | Precio de paquete por enfermedad | 2020–2021 |
| Radioterapia | 11000 – 50000 CNY | Precio por ítem | 2025–2026 |
| Quimioterapia | 6200 – 9000 CNY | Precio de paquete por enfermedad | 2020–2021 |
| Terapia dirigida | 88000 – 237000 CNY | Precio por ítem | 2025 |
| Inmunoterapia | 32043 – 42620 CNY | Precio por ítem | 2024–2025 |
Las barras comparten una sola escala en todas las filas de arriba: cada una empieza en la cifra publicada más baja de su fila y termina en la más alta. La cifra superior más alta de esta página es 237000 CNY. Cada fila conserva su propio año de datos y su criterio.
5 intervalos de costos para esta enfermedad, cada uno con su fuente en la página de la fila.
Los valores escritos en chino se citan tal como los publica la fuente.
Supervivencia a cinco años
Tasa de supervivencia a 5 años 55.7% IC del 95% 55.4–55.9
- Población
- Global (todos los estadios combinados) · Supervivencia relativa estandarizada por edad
- Período
- 2019–2021
- Publicador
- Centro Nacional del Cáncer de China
- Naturaleza del valor
- Valor estimado (análisis híbrido)
- Alcance del registro
- 281 registros de cáncer de base poblacional
- Disponibilidad de datos por estadio
- No publicado por estadio (la fuente solo publica la cifra global)
Los valores escritos en chino se citan tal como los publica la fuente.
Cómo leer esta cifra. Se publica para todos los estadios combinados, así que es un promedio de todas las personas de los datos del registro nacional y no un pronóstico para una persona. En la mayoría de los cánceres, el estadio en el momento del diagnóstico es el factor único más determinante de las diferencias de supervivencia: la supervivencia suele ser mayor cuando el cáncer se detecta en un estadio más temprano y menor cuando se detecta más tarde. Las comparaciones entre cánceres también dependen de con qué antelación o retraso suele diagnosticarse cada uno, así que una cifra más baja no significa por sí sola peor atención.
La cifra es de supervivencia relativa: compara a las personas diagnosticadas de este cáncer con personas de la misma edad y sexo de la población general, y está estandarizada por edad, así que no es la proporción de pacientes que siguen vivos a los cinco años. Se publica como un valor estimado (análisis híbrido) porque los informes de los registros llegan con retraso, así que el Centro Nacional del Cáncer modeló el período más reciente. Como contexto, la misma fuente publica una supervivencia relativa a cinco años del 43,7% para todos los cánceres combinados en 2019–2021.
Hospitales con un registro publicado para esta enfermedad
Seleccionados con fuentes de datos públicas oficiales
Estos hospitales se seleccionan de fuentes de datos públicas oficiales —los rankings de reputación por especialidad de hospitales de la Universidad de Fudan, la lista de especialidades clínicas clave nacionales y los centros nacionales de investigación clínica—, de modo que cada línea de una tarjeta se puede contrastar con su fuente publicada. No es un listado pagado ni promocionado.
Cómo se seleccionaron estos hospitales
Inclusión. Un hospital se lista para una enfermedad cuando la especialidad en la que esta se clasifica cumple al menos una de estas condiciones: un puesto o una nominación en el ranking de reputación por especialidad de hospitales de la Universidad de Fudan; un registro de especialidad clínica clave nacional de nivel A, B o C; o un centro nacional de investigación clínica o un laboratorio estatal clave en esa especialidad. La acreditación JCI se muestra como distintivo; nunca decide la inclusión ni el orden.
Orden. Paso 1: un puesto de Fudan entre 1 y 10 en la especialidad. Paso 2: otro puesto de Fudan, o una nominación. Paso 3: una especialidad clínica clave nacional de nivel A. Paso 4: una especialidad clínica clave nacional de nivel B. Paso 5: un centro nacional de investigación clínica o un laboratorio estatal clave en la especialidad, primero el centro y luego el laboratorio. Paso 6: una especialidad clínica clave nacional de nivel C, que es un registro que publicamos sin una fuente oficial independiente y que por eso se lista después de los demás.
Empates. Dentro de un mismo paso: primero el puesto de Fudan más alto, luego el nivel de especialidad clave más fuerte (A antes que B antes que C), luego la provincia, luego la ciudad y luego el nombre del hospital, el mismo orden provincia-ciudad-nombre que usa el directorio de hospitales. Se listan como máximo ocho hospitales.
Cuando la lista es corta. Cinco hospitales o más: se listan los ocho primeros. Tres o cuatro: se listan todos y un pliegue adicional añade los registros restantes hasta ocho, cada uno con su nivel de evidencia. Uno o dos: lo mismo, con ese pliegue abierto y una línea que indica cuántos hospitales tienen un historial público sólido. Ninguno: la página declara que no se encontró ningún historial público sólido y enlaza al directorio de especialidades. Nunca se inventa un puesto, una institución ni un recuento para rellenar la lista.
Los rankings de Fudan son el ranking de reputación por especialidad de hospitales más ampliamente reconocido por los clínicos chinos, publicado cada año por el instituto de gestión hospitalaria de la Universidad de Fudan.
-
Peking Union Medical College Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #1 https://www.fdygs.com/news2023-1.aspx
También en el ranking: Urología #8, Ginecología #1, Otorrinolaringología #4 en la lista de Fudan.
-
Zhongshan Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #2 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía general (nivel B) https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Investigación publicada
- A clinico-radiological model integrating baseline CT-derived body composition to predict prognosis in immunotherapy-treated metastatic colorectal cancer. European journal of radiology, 2026
- Corrigendum to “Cross-species single-cell and spatial transcriptomic mapping reveals EFNA1-EPHA4-mediated stem-like epithelial-macrophage crosstalk driving colorectal cancer progression” [Cancer Letters 649 (2026) 218495]. Cancer letters, 2026
1 estudio publicado más
PubMed indexa 3 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Cirugía torácica #6, Gastroenterología #9, Neumología #6 en la lista de Fudan.
-
West China Hospital, Sichuan University
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #3 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía general (nivel A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Cirugía gastrointestinal (nivel A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
También en el ranking: Cirugía torácica #4, Urología #2 (empatado), Otorrinolaringología #8 en la lista de Fudan.
-
Ruijin Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #4 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía general (nivel B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Investigación publicada
- Mesenchymal Tumors Feature a Spatially Defined Glial-Tip Cell Niche Around the Tumor Boundary in Microsatellite-Stable Colorectal Cancer. Cancer research, 2026
- Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights. Genes & diseases, 2027
PubMed indexa 2 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Cirugía torácica #7 (empatado), Neumología #5, Enfermedades infecciosas #6 en la lista de Fudan.
-
Chinese PLA General Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #5 https://www.fdygs.com/news2023-1.aspx
Investigación publicada
- Health technology assessment of robotic surgery for rectal cancer in China: protocol for a nationally multicentre prospective cohort study. BMJ open, 2026
- SFRP2 Potentiates Metastasis of Colon Cancer by Enhancing Snai1 Protein Stability via USP11. Journal of cellular and molecular medicine, 2026
PubMed indexa 2 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Urología #1, Otorrinolaringología #3, Gastroenterología #4 en la lista de Fudan.
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #6 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía general (nivel B) https://www.tjh.com.cn/contents/934/27291.html
- Cirugía gastrointestinal (nivel B) https://www.tjh.com.cn/contents/934/27291.html
También en el ranking: Urología #5, Ginecología #2, Neumología #8 en la lista de Fudan.
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #7 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía general (nivel A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Investigación publicada
- Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS(G12C) mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. The lancet. Gastroenterology & hepatology, 2026
PubMed indexa 1 artículo sobre esta enfermedad que menciona este hospital.
También en el ranking: Urología #9, Enfermedades infecciosas #2, Cirugía torácica nominado en la lista de Fudan.
-
The First Affiliated Hospital, Sun Yat-sen University
Ranking de reputación por especialidad de Fudan 2023
- Cirugía general #8 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
Investigación publicada
- Correction: Effect and potential mechanism of oncometabolite succinate promotes distant metastasis of colorectal cancer by activating STAT3. BMC gastroenterology, 2024
- Release of volatile organic compounds (VOCs) from colorectal cancer cell line LS174T. Analytical biochemistry, 2019
PubMed indexa 2 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Ginecología #9, Otorrinolaringología #5, Gastroenterología #8 en la lista de Fudan.
Ensayos clínicos (tratamientos en investigación)
Además de la atención estándar, es posible que actualmente haya estudios de investigación clínica para Colorectal cancer abiertos a participantes en China. Los tratamientos en estudio no han sido aprobados por el regulador como terapia estándar: son investigación clínica, no tratamiento de rutina. Cada registro indica el investigador principal y el hospital que realiza el estudio. Si te interesa, contacta con el hospital para preguntar por los criterios de elegibilidad y decide si solicitas participar.
-
Estudio Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer：A Phase 2, Randomized Controlled Study
- Hospital
- Peking Union Medical College Hospital
- Estado
- En reclutamiento
- Registro
- NCT07200141
-
Estudio Deferred Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After NED in Colorectal Cancer： A Phase II, Single-Arm Clinical Trail.
- Investigador principal
- Jinbo Yue · Director of Radiation Oncology Department
- Hospital
- Shandong Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06778382
-
Estudio A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Estado
- En reclutamiento
- Registro
- NCT06434597
-
Estudio A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
- Investigador principal
- Zhongtao Zhang · The professor
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Estado
- En reclutamiento
- Registro
- NCT06312982
-
Estudio Efficacy and Safety Study of Thymalfasin in Combination with Targeted Immunotherapy (Regorafenib and Tislelizumab) in Patients with Advanced PMMR/MSS Colorectal Cancer Who Failed Standard of Care: a Multicenter, Open-label, Randomized, Controlled Clinical Study
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Estado
- En reclutamiento
- Registro
- NCT06829355
118 estudios registrados más
-
Estudio A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT07284849
-
Estudio The Value of Bowel Sounds in Evaluating Postoperative Intestinal Function Recovery in Colorectal Cancer Patients: A Prospective Cohort Study
- Hospital
- Zhongnan Hospital of Wuhan University
- Estado
- En reclutamiento
- Registro
- NCT07705139
-
Estudio Exploratory Study of NK510 Cell Therapy in the Treatment of Recurrent and Refractory Advanced Gastric Cancer and Colorectal Cancer
- Hospital
- Nanjing Drum Tower Hospital
- Estado
- En reclutamiento
- Registro
- NCT07166263
-
Estudio Efficacy of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial
- Hospital
- Jiangsu Province Hospital
- Estado
- En reclutamiento
- Registro
- NCT05709249
-
Estudio A Prospective, Exploratory Study on the Efficacy of Neoadjuvant Chemoradiotherapy Combined With QL1706 in Patients With MSS-type Low-stage Rectal Cancer
- Investigador principal
- Wei Zhang
- Estado
- En reclutamiento
- Registro
- NCT07866313
-
Estudio A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)
- Investigador principal
- Zhen Zhang · Study Principal Investigator
- Hospital
- Fudan University Shanghai Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT06281405
-
Estudio A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
- Investigador principal
- Junjie Peng · Prof.
- Hospital
- Fudan University Shanghai Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT05954429
-
Estudio A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
- Investigador principal
- Guoxiang Cai · Professor
- Hospital
- Fudan University Shanghai Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT06903325
-
Estudio Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT07750951
-
Estudio Short-course Radiotherapy(SCRT) Followed by Ivonescimab(AK112) and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer(LARC）: A Single-arm, Single-center, Exploratory, Phase II Clinical Study
- Investigador principal
- Zhenyu Lin · Director
- Hospital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Estado
- En reclutamiento
- Registro
- NCT06802666
-
Estudio A Phase II Exploratory Multicenter Randomized Controlled Clinical Trial to Evaluate the Effectiveness of Neoadjuvant Short-Course Radiotherapy (SCRT) Followed by CAPEOX Chemotherapy and Serplulimab in Microsatellite Stable (MSS) or Proficient Mismatch Repair (pMMR) Rectal Cancer With Synchronous Oligometastases
- Investigador principal
- Feng Ye · chief physician
- Hospital
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06850103
-
Estudio Oncologic Outcomes of Single-incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Multi-center, Prospective, Open Label, Non-inferiority, Randomized Controlled Trial
- Investigador principal
- Zhao Ren · Chief Physicion
- Hospital
- Ruijin Hospital
- Estado
- En reclutamiento
- Registro
- NCT04527861
-
Estudio Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study
- Hospital
- Nanfang Hospital
- Estado
- En reclutamiento
- Registro
- NCT07542171
-
Estudio A Multicenter, Prospective, Phase II Exploratory Study on the First-line Treatment of MSS/ PMMR-type Advanced Colorectal Cancer With Adebrelimab Combined With Simvastatin and Targeted and Chemotherapy
- Hospital
- Jiangsu Province Hospital
- Estado
- En reclutamiento
- Registro
- NCT07718490
-
Estudio Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
- Investigador principal
- Qian Peng · chief physician
- Hospital
- Sichuan Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06244537
-
Estudio China Colorectal Cancer Screening Trial 1 (C-Cost1): Colonoscopy Versus FIT Versus FIT Plus Blood Test in the Average Risk Population
- Investigador principal
- Ding Ke-Feng · Professor
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07090291
-
Estudio ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
- Investigador principal
- Zhu Yuping · MD
- Hospital
- Zhejiang Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06609551
-
Estudio Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer (SCRIT): A Multicenter Phase III Randomized Controlled Trial
- Investigador principal
- Jinbo Yue · Director of Department Radiation Oncology
- Hospital
- Shandong Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07686640
-
Estudio Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT): A Single-arm, Exploratory, Phase II Trial
- Investigador principal
- Jinbo Yue · Director of Radiation Oncology Department
- Hospital
- Shandong Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07026422
-
Estudio A Randomized, Multicenter, Controlled Study of Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
- Investigador principal
- Yuan-Sheng Zang
- Estado
- En reclutamiento
- Registro
- NCT06603376
-
Estudio A Prospective Single-arm Phase II Clinical Study Evaluating Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma in High-risk Patients With Rectal Cancer Undergoing Low Anterior Resection
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07833319
-
Estudio Neoadjuvant Chemotherapy and Tislelizumab (PD-1 Inhibitior) for Locally Advanced Rectal Cancer: a Single-center, Prospective, Phase II Study
- Hospital
- The Affiliated Hospital of Qingdao University
- Estado
- En reclutamiento
- Registro
- NCT06647680
-
Estudio A Randomized, Two-Arm, Open-Label Phase II Trial of Low-Dose Radiotherapy Sensitization Combined With Pucotenlimab and CAPEOX as Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Adenocarcinoma
- Investigador principal
- Pei-Rong Ding · Director of the Department of Colorectal Surgery
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07448142
-
Estudio Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer: a Prospective，Multicentre, Single-arm Study
- Estado
- En reclutamiento
- Registro
- NCT06613165
-
Estudio The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
- Investigador principal
- Hu Jiajia · Deputy director
- Hospital
- Ruijin Hospital
- Estado
- En reclutamiento
- Registro
- NCT06601075
-
Estudio Survival Benefit of Compound Kushen Injection in Treatment of Advanced Colorectal Cancer Based on Real World Registration Platform
- Investigador principal
- Jie Li · Vice President
- Hospital
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Estado
- En reclutamiento
- Registro
- NCT05894694
-
Estudio FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: Protocol of an Open-Label, Multicentre, Randomised, Controlled, Phase Ⅱ Trial
- Investigador principal
- Quanda Liu · Chief physician
- Hospital
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Estado
- En reclutamiento
- Registro
- NCT07333053
-
Estudio Laparoscopic Ileocecal-Sparing Right Hemicolectomy for Cancer of the Hepatic Flexure and Proximal Transverse Colon -- A Prospective, Multicenter Randomized Control Clinical Trial
- Investigador principal
- Ding Ke-Feng · Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT05923255
-
Estudio A Single-arm, Single-center Clinical Study of Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
- Hospital
- Ningbo Medical Center Lihuili Hospital
- Estado
- En reclutamiento
- Registro
- NCT06613113
-
Estudio An Exploratory Study on Gene Methylation Detection of Colorectal Cancer（CRC）
- Investigador principal
- Zhenyuan Qian · associate senior doctor
- Hospital
- Zhejiang Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07033156
-
Estudio A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer
- Hospital
- Peking University Shenzhen Hospital
- Estado
- En reclutamiento
- Registro
- NCT07462650
-
Estudio A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer
- Hospital
- Peking University Shenzhen Hospital
- Estado
- En reclutamiento
- Registro
- NCT07589517
-
Estudio Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI
- Investigador principal
- xiaochun meng · The Director of Diagnostic Radiology Department
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT05523245
-
Estudio Laparoscopic Rectal Irrigation for the Prevention of Local Recurrence After Radical Resection of Mid-to-Low Rectal Cancer: A Prospective, Multicenter, Randomized, Open-label, Parallel-controlled Clinical Study
- Investigador principal
- Yanhong Deng · chief physician
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT07512232
-
Estudio Effects of Preoperative Oral Mmidazolam on Postoperative Pain in Sleep Disturbance or Anxiety Patients Undergoing Laparoscopic Colorectal Cancer Resection- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study
- Investigador principal
- SanQing Jin · professor
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT06407518
-
Estudio Toripalimab Plus Celecoxib With Response-adapted Non-operative Management for Mismatch Repair-deficient or Microsatellite Instability-high Locally Advanced Colorectal Cancer (PICC-3): a Multicenter, Single-arm, Phase 2 Trial
- Investigador principal
- Yanhong Deng · Professor
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT06903858
-
Estudio A Prospective, Randomized, Open, Parallel-controlled, Superiority Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
- Investigador principal
- Yanhong Deng · chief physician
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT06485609
-
Estudio Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer: A Prospective, Single-arm, Phase II Study
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT07297004
-
Estudio Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Single-Arm, Phase 2 Trial
- Investigador principal
- Yanhong Deng · Professor
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT05450029
-
Estudio A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT06662786
-
Estudio Transanal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer (TaLaR): a Multicentre Randomised Clinical Trial
- Investigador principal
- Yanhong Deng · MD
- Hospital
- Peking Union Medical College Hospital
- Estado
- En reclutamiento
- Registro
- NCT02966483
-
Estudio An Exploratory Study Investigating the Combination of Chidamide, Regorafenib, Plus Iparomlimab and Tuvonralimab for the Treatment of Drug-esistant and Efractory Dvanced Colorectal Cancer
- Estado
- En reclutamiento
- Registro
- NCT06930118
-
Estudio Phase II Study of Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
- Investigador principal
- Zhan Wang
- Estado
- En reclutamiento
- Registro
- NCT07398326
-
Estudio CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
- Estado
- En reclutamiento
- Registro
- NCT06881537
-
Estudio A Dose-expansion Trial Exploring the Safety and Efficacy of Intravenous HNF4α srRNA in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
- Investigador principal
- Wei-Fen Xie
- Estado
- En reclutamiento
- Registro
- NCT07050394
-
Estudio Multi-omics Study for Early Detection of Colorectal Cancer Based on Liquid Biopsy Technology
- Investigador principal
- Ding Ke-Feng · Chief physician
- Hospital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06220617
-
Estudio A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
- Investigador principal
- Wang Chang · Director
- Hospital
- The First Hospital of Jilin University
- Estado
- En reclutamiento
- Registro
- NCT06979908
-
Estudio Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
- Investigador principal
- Pengyu Chang · Chief Physician
- Hospital
- The First Hospital of Jilin University
- Estado
- En reclutamiento
- Registro
- NCT07505472
-
Estudio A Prospective Study of Levoleucovorin/5-FU Co-Infusion Combined With Liposomal Irinotecan ±Cetuximab/Bevacizumab as Second-Line Therapy for MSS Metastatic Colorectal Cancer
- Hospital
- The First Hospital of Jilin University
- Estado
- En reclutamiento
- Registro
- NCT07559760
-
Estudio Efficacy and Safety of Neoadjuvant Long-course Chemoradiation Plus Tislelizumab in Mid-low Locally Advanced Rectal Cancer: a Phase II, Multi-center, Open-label, Randomized Controlled Trial (POLARSTAR Trial)
- Investigador principal
- Zhongtao Zhang · Director
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Estado
- En reclutamiento
- Registro
- NCT05245474
-
Estudio Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
- Investigador principal
- Lin Wang · Unit III & Ostomy Service, Gastrointestinal Cancer Center
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06209099
-
Estudio Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery
- Investigador principal
- Tao Fu · Director of Department of GI Surgery II
- Hospital
- Renmin Hospital of Wuhan University
- Estado
- En reclutamiento
- Registro
- NCT03972956
-
Estudio Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Middle and Low Rectal Cancer (mRCAT-E): An Open-label, Single-arm, Prospective Multicenter Clinical Trial
- Investigador principal
- Zhangfa Song · Vice president
- Hospital
- Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT07068763
-
Estudio Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer: a Multicenter, Randomized Controlled Trial
- Investigador principal
- Zhangfa Song · Vice director
- Hospital
- Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06167967
-
Estudio An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
- Hospital
- Fujian Medical University Union Hospital
- Estado
- En reclutamiento
- Registro
- NCT05253651
-
Estudio A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L/pMMR Metastatic Colorectal Cancer
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT07133750
-
Estudio TME vs TME+nCT in Low-risk LARC
- Investigador principal
- Yanhong Deng
- Estado
- En reclutamiento
- Registro
- NCT05984485
-
Estudio An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer
- Hospital
- Beijing Hospital
- Estado
- En reclutamiento
- Registro
- NCT07525206
-
Estudio The Effectiveness of Deferred Adjuvant Therapy Guided by Dynamic Monitoring Minimal Residue Disease in Resectable High-risk Stage II and Low-risk Stage III Colon Cancer: an Open-label, Multicenter, Phase II Clinical Study
- Investigador principal
- Gong Chen · Professor
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT06204484
-
Estudio Irinotecan in Combination With Trifluridine-tipiracil and Bevacizumab in Pre-treated Metastatic Colorectal Cancer
- Hospital
- Qilu Hospital of Shandong University
- Estado
- En reclutamiento
- Registro
- NCT06242067
-
Estudio Hypofractionated Radiotherapy Combined With Irinotecan Hydrochloride Liposome, 5-FU, Leucovorin, PD-1 Antibody and Target Therapy in Locally Recurrent Rectal Cancer(NOVELTY-R)
- Investigador principal
- Zhen Zhang · Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Hospital
- Fudan University Shanghai Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07183865
-
Estudio Use of Probe-based Confocal Laser Endomicroscopy to Perform Targeted Optical Biopsy for Local Rectal Scars in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
- Hospital
- Nanfang Hospital
- Estado
- En reclutamiento
- Registro
- NCT05316103
-
Estudio Right Gastroepiploic Mesentery Metastasis in Advanced Colon Cancer Locating at or Close to the Hepatic Flexure
- Investigador principal
- Jichao Qin · Professor
- Hospital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Estado
- En reclutamiento
- Registro
- NCT04980287
-
Estudio A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07549412
-
Estudio Clinical Study of Second-line Treatment of Patients With Advanced Colorectal Cancer With Irinotecan Liposome (II), Fluorouracil in Combination With Bevacizumab or Cetuximab
- Hospital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06540326
-
Estudio Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
- Hospital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06992648
-
Estudio Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial
- Investigador principal
- QIAN LIU · Professor
- Hospital
- Peking Union Medical College Hospital
- Estado
- En reclutamiento
- Registro
- NCT06146946
-
Estudio A Prospective, Multicenter, Randomized, Parallel Controlled Study Comparing Huaier Granules With Capecitabine Monotherapy for the Prevention of Recurrence and Metastasis After Radical Resection of Stage II Colorectal Cancer
- Investigador principal
- Sanjun Cai · professor
- Hospital
- Third Affiliated Hospital of Harbin Medical University
- Estado
- En reclutamiento
- Registro
- NCT06090994
-
Estudio A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT07653685
-
Estudio A Phase Ib/II Clinical Study Evaluating TQB2922 for Injection and Chemotherapy in Combination With or Without Bevacizumab in Subjects With RAS/BRAF Wild-Type Advanced Colorectal Cancer Who Have Failed Chemotherapy
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT07044908
-
Estudio Open, Parallel, Randomized Controlled, Non-inferior, Phase III Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
- Investigador principal
- Kai Li · Deputy Director of surgical Oncology
- Hospital
- First Hospital of China Medical University
- Estado
- En reclutamiento
- Registro
- NCT06637215
-
Estudio A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT06750094
-
Estudio A Study to Evaluate the Efficacy and Safety of a First-line Treatment for Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
- Investigador principal
- Dai, Guanghai · Professor
- Hospital
- Chinese PLA General Hospital
- Estado
- En reclutamiento
- Registro
- NCT07391618
-
Estudio A Multicenter Randomized Clinical Trial to Assess the Advantages of Robotic Total Mesorectal Excision in Preserving External Sphincter in Patients with Middle and Low Rectal Cancer.
- Investigador principal
- Quan Wang · Professor
- Hospital
- The First Hospital of Jilin University
- Estado
- Aún sin reclutar
- Registro
- NCT06105203
-
Estudio Exploratory Study on the Efficacy and Safety of Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07394192
-
Estudio A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Colorectal Cancer With Chemotherapy Combined With Anti-Angiogenic Targeted Agents
- Investigador principal
- Bin Xiong, MD · Chief Physician
- Hospital
- Zhongnan Hospital of Wuhan University
- Estado
- Aún sin reclutar
- Registro
- NCT06470178
-
Estudio A National Multicenter, Prospective, Randomized Controlled Study of Serplulimab Injection Combined With Bevacizumab to Improve the Complete Response Rate of Neoadjuvant Therapy for Locally Advanced Stage Intermediate and Low Rectal Cancer
- Estado
- Aún sin reclutar
- Registro
- NCT07134218
-
Estudio Efficacy and Safety of Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer: A Prospective, Single-arm Observational Study
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- Aún sin reclutar
- Registro
- NCT06617052
-
Estudio Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy
- Investigador principal
- Hui Yang · principal investigator
- Hospital
- Sichuan Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07172087
-
Estudio A Non-randomised External Controlled Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Surgery
- Investigador principal
- Hui Yang · Principal Investigator
- Hospital
- Sichuan Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06860685
-
Estudio A Prospective Single-Center Observational Study Evaluating Concordance Between Large Language Model-Generated Recommendations and Multidisciplinary Team Recommendations in Rectal Cancer
- Investigador principal
- Jinbo Yue · Professor
- Hospital
- Shandong Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07595107
-
Estudio Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal High-Risk or Very High-Risk Patients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
- Investigador principal
- Quan Wang · Prof.
- Hospital
- The First Hospital of Jilin University
- Estado
- Aún sin reclutar
- Registro
- NCT05998122
-
Estudio A Prospective, Phase II, Single-Arm Study on the Efficacy and Safety of Neoadjuvant Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
- Investigador principal
- Yingchi Yang · Professor
- Hospital
- Beijing Friendship Hospital, Capital Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07397442
-
Estudio Development and Validation of a Colorectal Cancer Diagnostic Model: A Multicenter Study in China (CCDM-CN)
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07692555
-
Estudio Comparison of Large Language Models and Expert Multidisciplinary Team Decisions in Colorectal Cancer
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07045207
-
Estudio Phase Ib/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of MRG007 Combination Therapy in Patients With Advanced Colorectal Cancer
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07737600
-
Estudio A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.
- Hospital
- Zhongnan Hospital of Wuhan University
- Estado
- Aún sin reclutar
- Registro
- NCT07515963
-
Estudio PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS
- Investigador principal
- Yong Li, MD · Chief Physician of Gastrointestinal Surgery
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06391905
-
Estudio A Single-Arm, Phase II, Multicenter Study of Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
- Estado
- Aún sin reclutar
- Registro
- NCT07819604
-
Estudio A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
- Hospital
- First Hospital of China Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07730489
-
Estudio Exploratory Clinical Study of SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
- Investigador principal
- Yunpeng Liu · Professor
- Hospital
- First Hospital of China Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06666166
-
Estudio A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
- Investigador principal
- Dai, Guanghai · Professor,Chief Physician
- Hospital
- Chinese PLA General Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07797244
-
Estudio Exploring the Effects of Magnesium Ions on Peripheral Neuropathy, Serum Magnesium Ion Concentration,Sleep Quality, and Quality of Life in Patients With Colorectal Cancer Receiving Chemotherapy.
- Hospital
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07346469
-
Estudio A Prospective, Multicenter, Single-Arm Phase II Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (cT1-3N0M0)
- Investigador principal
- Bo Yi · Chief Physician
- Hospital
- Chongqing University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07543848
-
Estudio A Prospective Single-Arm Phase II Clinical Study of Neoadjuvant Short-Course Radiotherapy With Simultaneous Integrated Boost Combined With Capecitabine-Oxaliplatin and PD-1 Inhibitor Therapy in High-Risk Locally Advanced Rectal Cancer
- Investigador principal
- Yanhong Deng · M.D.
- Hospital
- The Sixth Affiliated Hospital, Sun Yat-sen University
- Estado
- Aún sin reclutar
- Registro
- NCT07297030
-
Estudio A Prospective, Single-arm, Multicenter Phase II Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
- Investigador principal
- Liangjun Zhu M.M. · Chief Physician, Department of Medical Oncology
- Hospital
- Jiangsu Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07446387
-
Estudio A Randomized, Multicenter Clinical Study of Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
- Investigador principal
- Ji Zhu · Coordinating Investigator
- Hospital
- Zhejiang Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07074353
-
Estudio A Randomized Controlled Trial of Fluorescence Laparoscopic Navigation of the Extent of Lymph Node Dissection for High Rectal Cancer and Sigmoid Colon Cancer
- Investigador principal
- Jianqiang Tang · Associate professor
- Hospital
- Anhui Provincial Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT05730595
-
Estudio Effect of an Individualized Urinary Catheter Management Strategy on the Safety and Efficacy of Early Catheter Removal After Mid-Low Rectal Cancer Surgery: A Single-Center Randomized Controlled Trial
- Investigador principal
- Yuchen Guo, Ph.D. · Prof.
- Hospital
- The First Hospital of Jilin University
- Estado
- Aún sin reclutar
- Registro
- NCT07346586
-
Estudio To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
- Hospital
- Tianjin Medical University Cancer Institute & Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07738042
-
Estudio The Safety and Efficacy of Autologous Probiotics in Patients With Defunctioning Ileostomy Following Low Anterior Resection for Rectal Cancer.
- Investigador principal
- Lin Wang · surgeon-in-charge
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07366047
-
Estudio SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study
- Investigador principal
- Jian Li · Chief Physician
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07700719
-
Estudio Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers (NOMIC Trial)
- Investigador principal
- Xiaokang Lei · Principal Investigator
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07656740
-
Estudio A Phase II Study Evaluating the Efficacy and Safety of Neoadjuvant Therapy With MRI-Guided Involve-site Short-Course Radiotherapy Combined With Immunotherapy and Chemotherapy for Locally Advanced Rectal Cancer
- Investigador principal
- Longhao Li · M.D.
- Hospital
- The First Affiliated Hospital of Chongqing Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07161115
-
Estudio An Intelligent Voice-interactive Tailored Communication System (ScreenTalk) for Enhancing Colorectal Cancer Screening Among First-degree Relatives of Patients: a Randomized Type I Hybrid Effectiveness-implementation Trial
- Investigador principal
- Yang Bai · Associate Professor
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- Aún sin reclutar
- Registro
- NCT06710860
-
Estudio The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study
- Investigador principal
- Tao Fu · Head of Department of GI Surgery II
- Hospital
- Renmin Hospital of Wuhan University
- Estado
- Aún sin reclutar
- Registro
- NCT03127111
-
Estudio Safety and Efficacy Study of Single-port Robotic Versus Multi-port Robotic Radical Rectal Cancer Surgery: A Multi-center, Prospective, Open Label, Non-inferiority, Randomized Controlled Trial
- Investigador principal
- Zhao Ren · Chief Physicion
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06943690
-
Estudio Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis
- Investigador principal
- Taiyuan Li · chief physician
- Hospital
- The First Affiliated Hospital of Nanchang University
- Estado
- Aún sin reclutar
- Registro
- NCT07029464
-
Estudio QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study
- Investigador principal
- Xi Shi · MD
- Hospital
- The First Affiliated Hospital of Fujian Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07649473
-
Estudio Node-sparing Modified Short-Course Radiation Combined With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer : A Randomized, Prospective, Multicenter, Open-label Clinical Trial
- Investigador principal
- Zhangfa Song · Professor
- Hospital
- Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
- Estado
- Aún sin reclutar
- Registro
- NCT06594692
-
Estudio A Prospective, Multicenter, Randomized Controlled Trial of the Effectiveness of Robotic Versus Laparoscopic Surgery for Right Colon Cancer
- Investigador principal
- Zhangfa Song · Professor
- Hospital
- Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
- Estado
- Aún sin reclutar
- Registro
- NCT06421974
-
Estudio Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer
- Hospital
- Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
- Estado
- Aún sin reclutar
- Registro
- NCT06079242
-
Estudio Short-Course Radiotherapy Followed by Liposomal Irinotecan, Capecitabine, and Camrelizumab as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Low Rectal Cancer: A Prospective Single-Arm Phase II Trial Protocol
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07521605
-
Estudio Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07686796
-
Estudio A Single-Arm, Exploratory Study of Iparomlimab and Tuvonralimab (QL1706) Plus XELOX as Neoadjuvant Therapy in Patients With Microsatellite Stable (pMMR/MSS) Resectable Stage III Colon Cancer
- Investigador principal
- Jing Hao · Deputy Director, Department of Oncology
- Hospital
- Qilu Hospital of Shandong University
- Estado
- Aún sin reclutar
- Registro
- NCT07156682
-
Estudio Multicenter Clinical Validation of a Novel Strategy for Early Diagnosis and Recurrence Monitoring in Colorectal Cancer
- Investigador principal
- Jie Liu · Professor
- Hospital
- Huashan Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06991452
-
Estudio Preservation Versus Dissection of Inferior Mesenteric Artery Lymph Nodes of Robotic Radical Resection for Mid/Low Rectal Cancer (REAL2): A Multicenter Randomized Controlled Trial
- Investigador principal
- Xu jianmin · Chair of Colorectal Surgery Department
- Hospital
- Zhongshan Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06956976
-
Estudio Savolitinib Plus Cetuximab and FOLFOX Chemotherapy Versus Cetuximab and FOLFOX Chemotherapy as First-line Treatment for RAS/BRAF Wild-type Metastatic Colorectal Cancer: a Prospective, Randomized, Controlled, Multicenter, Open-label Study
- Investigador principal
- Xu jianmin
- Estado
- Aún sin reclutar
- Registro
- NCT07683403
Esta página solo comparte información de estudios registrados públicamente. No recomienda ni anima a participar en ningún estudio. La participación es totalmente voluntaria y los riesgos de un tratamiento no aprobado son desconocidos; contacta directamente con el hospital para conocer los criterios de elegibilidad y los detalles del consentimiento informado.
Terapias avanzadas: qué está autorizado y qué está en ensayos
Hospitales con un registro de especialidad clave nacional
Mostrar los registros de hospitales 50 hospitales con un registro de especialidad clave
Cada fila es un hospital con un registro de especialidad clínica clave nacional en una especialidad en la que se clasifica esta enfermedad. Es un registro de listados publicados, no una recomendación ni un ranking.
50 hospitales con un registro de especialidad clave nacional que coincide.
Los valores escritos en chino se citan tal como los publica la fuente.
Lo que reportan los pacientes
Solo cifras agregadas: un resultado nacional citado con su fuente y el año al que se refiere. No es el testimonio de un paciente ni una afirmación sobre una sola persona.
Según lo publicado en National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Fuente: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Nivel A
Todos los temas de terapias y acceso
Preguntas sobre esta enfermedad
No podemos dar asesoramiento médico, pero sí responder preguntas sobre esta página y sobre cómo organizar un tratamiento en China.
Códigos CIE
Mostrar la tabla de códigos 13 códigos CIE
| Versión | Código | Nombre en esa versión |
|---|---|---|
| ICD-10-WHO | C18 | Malignant neoplasm of colon |
| ICD-10-WHO | C18.0 | Caecum |
| ICD-10-WHO | C18.1 | Appendix |
| ICD-10-WHO | C18.2 | Ascending colon |
| ICD-10-WHO | C18.3 | Hepatic flexure |
| ICD-10-WHO | C18.4 | Transverse colon |
| ICD-10-WHO | C18.5 | Splenic flexure |
| ICD-10-WHO | C18.6 | Descending colon |
| ICD-10-WHO | C18.7 | Sigmoid colon |
| ICD-10-WHO | C18.8 | Overlapping lesion of colon |
| ICD-10-WHO | C18.9 | Colon, unspecified |
| ICD-10-WHO | C19 | Malignant neoplasm of rectosigmoid junction |
| ICD-10-WHO | C20 | Malignant neoplasm of rectum |
Las filas son las entradas CIE-10 de la OMS para esta enfermedad, citadas tal como se publicaron.
Fuente y evidencia
- URL de la fuente
- https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
- Esquema de la fuente
- https
- Tipo de fuente
- Comisión de salud provincial
- Nivel de evidencia
- A - declarado por una comisión de salud, un instituto nacional de investigación o una universidad
- Recuperado el
- 2026-09-24